Details of the Drug Reposition

General Information of This Drug (ID: DMCEW64)

Drug Name
Ceftriaxone   DMCEW64
Synonyms
Biotrakson; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxonum; Ceftriazone; Longacef; Longaceph; Rocefin; Rocephin; Rocephine; CEFTRIAXONE SODIUM; Ceftriaxone intravenous; Ro 139904; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone, Disodium Salt; Ceftriaxonum [INN-Latin]; DRG-0071; Ro13-9904; Rocephin (TN); Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ro-13-9904; (6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
11 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Staphylococcal pneumonia DIS28ZSZ N.A. Approved [1]
Pneumococcal meningitis DISM5U0L N.A. Approved [1]
Meningococcal meningitis DISCKTAT N.A. Approved [1]
Gonococcal infection of joint DISE12BW N.A. Approved [1]
Escherichia coli meningitis DISN1LGK N.A. Approved [1]
Endometritis DISHGJ6G N.A. Approved [1]
Chancroid DISMVLOF N.A. Approved [1]
Bacterial arthritis DIS8R241 N.A. Approved [1]
Acute gonococcal cervicitis DIS4LKDT N.A. Approved [1]
Bacterial infection DIS5QJ9S 1A00-1C4Z Approved [2]
Bacteremia DIS6N9RZ 1A73 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Indications(s)
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Acute gonococcal endometritis DISZ8BW7 N.A. Withdrawn [3]
------------------------------------------------------------------------------------
4 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Bacterial meningitis DISRP9SL N.A. Discontinued in Phase 2 [4]
Rhinoscleroma DISNSWVK N.A. Discontinued in Phase 2 [5]
Escherichia coli infection DISPP65M 1A03 Discontinued in Phase 2 [6]
Gonorrhea DISQ5AO6 1A7Z Discontinued in Phase 2 [7]
------------------------------------------------------------------------------------
2 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Streptococcal meningitis DISQ65JM N.A. Discontinued in Phase 1 [8]
Bacterial pneumonia DISPW7PH CA40.0 Discontinued in Phase 1 [9]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pelvic inflammatory disease DISWQR4J GA05 Investigative [1]
------------------------------------------------------------------------------------

References

1 Ceftriaxone FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5326).
3 Evidence of Haloperidol Absorption After Topical Administration
4 Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
5 Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
6 Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
7 Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
8 Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
9 ClinicalTrials.gov (NCT01347866) Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer